Docetaxel for injection (Albumin-bound)

Phase 3Small molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Docetaxel for injection (Albumin-bound) is one of 121 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

120

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaRecruiting

Pancreatic CancerNot yet recruiting

Gastric CancerRecruiting

Locally Advanced Unresectable Esophageal Squamous CarcinomaNot yet recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Recruiting

Pancreatic CancerPhase 3

Not yet recruiting

Gastric CancerPhase 3

Recruiting

Locally Advanced Unresectable Esophageal Squamous CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Docetaxel for injection (Albumin-bound)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

2 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

1 10

PEG-Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Pancreatic Cancer

NCT06492941

Q2 2027

Phase 3Recruiting

Gastric Cancer

NCT06296706

Q4 2027

Phase 2Recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06947291

Q2 2028

Phase 1/2Not yet recruiting

Locally Advanced Unresectable Esophageal Squamous Carcinoma

NCT06136988

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer

Not yet recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT06492941·142 enrolled

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05616494·53 enrolled

Gastric Cancer2 trials

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05705635·100 enrolled

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT06296706·630 enrolled

Locally Advanced Unresectable Esophageal Squamous Carcinoma1 trial

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Not yet recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT06136988·129 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06947291·350 enrolled

Tics1 trial

The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04811118·27 enrolled

1 more indication

Ovarian Cancer1 trial

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05325229·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Docetaxel for injection (Albumin-bound). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetaxel for injection (Albumin-bound) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docetaxel for injection (Albumin-bound). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Docetaxel for injection (Albumin-bound)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Pancreatic Cancer2 trials

Gastric Cancer2 trials

Locally Advanced Unresectable Esophageal Squamous Carcinoma1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Tics1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News